A pilot randomized controlled trial comparing a novel compassion and metacognition approach for schizotypal personality disorder with a combination of cognitive therapy and psychopharmacological treatment
© 2023. The Author(s)..
BACKGROUND: Schizotypal personality disorder is characterized by a pervasive pattern of maladaptive behavior that has been associated with the liability for schizophrenia. Little is known about effective psychosocial interventions. This pilot non-inferiority randomized controlled trial aimed to compare a novel form of psychotherapy tailored for this disorder and a combination of cognitive therapy and psychopharmacological treatment. The former treatment - namely, Evolutionary Systems Therapy for Schizotypy-integrated evolutionary, metacognitively oriented, and compassion focused approaches.
METHODS: Thirty-three participants were assessed for eligibility, twenty-four randomized on a 1:1 ratio, nineteen included in the final analysis. The treatments lasted 6 months (24 sessions). The primary outcome was change across nine measurements in personality pathology, the secondary outcomes were remission from diagnosis and pre-post changes in general symptomatology and metacognition.
RESULTS: Primary outcome suggested a non-inferiority of the experimental treatment in respect to control condition. Secondary outcomes reported mixed results. There was no significant difference in terms of remission, but experimental treatment showed a larger reduction of general symptomatology (η2 = 0.558) and a larger increase in metacognition (η2 = 0.734).
CONCLUSIONS: This pilot study reported promising results about the effectiveness of the proposed novel approach. A confirmatory trial on large sample size is needed to provide evidence about relative effectiveness of the two treatment conditions.
TRIAL REGISTRATION: ClinicalTrials.gov; NCT04764708; Registration day 21/02/2021.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
BMC psychiatry - 23(2023), 1 vom: 20. Feb., Seite 113 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cheli, Simone [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Compassion |
|---|
| Anmerkungen: |
Date Completed 23.02.2023 Date Revised 24.02.2023 published: Electronic ClinicalTrials.gov: NCT04764708 Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12888-023-04610-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353100897 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353100897 | ||
| 003 | DE-627 | ||
| 005 | 20231226055230.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12888-023-04610-5 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1176.xml |
| 035 | |a (DE-627)NLM353100897 | ||
| 035 | |a (NLM)36803673 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cheli, Simone |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A pilot randomized controlled trial comparing a novel compassion and metacognition approach for schizotypal personality disorder with a combination of cognitive therapy and psychopharmacological treatment |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.02.2023 | ||
| 500 | |a Date Revised 24.02.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT04764708 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a BACKGROUND: Schizotypal personality disorder is characterized by a pervasive pattern of maladaptive behavior that has been associated with the liability for schizophrenia. Little is known about effective psychosocial interventions. This pilot non-inferiority randomized controlled trial aimed to compare a novel form of psychotherapy tailored for this disorder and a combination of cognitive therapy and psychopharmacological treatment. The former treatment - namely, Evolutionary Systems Therapy for Schizotypy-integrated evolutionary, metacognitively oriented, and compassion focused approaches | ||
| 520 | |a METHODS: Thirty-three participants were assessed for eligibility, twenty-four randomized on a 1:1 ratio, nineteen included in the final analysis. The treatments lasted 6 months (24 sessions). The primary outcome was change across nine measurements in personality pathology, the secondary outcomes were remission from diagnosis and pre-post changes in general symptomatology and metacognition | ||
| 520 | |a RESULTS: Primary outcome suggested a non-inferiority of the experimental treatment in respect to control condition. Secondary outcomes reported mixed results. There was no significant difference in terms of remission, but experimental treatment showed a larger reduction of general symptomatology (η2 = 0.558) and a larger increase in metacognition (η2 = 0.734) | ||
| 520 | |a CONCLUSIONS: This pilot study reported promising results about the effectiveness of the proposed novel approach. A confirmatory trial on large sample size is needed to provide evidence about relative effectiveness of the two treatment conditions | ||
| 520 | |a TRIAL REGISTRATION: ClinicalTrials.gov; NCT04764708; Registration day 21/02/2021 | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Compassion | |
| 650 | 4 | |a Evolution | |
| 650 | 4 | |a Evolutionary systems therapy for schizotypy | |
| 650 | 4 | |a Metacognition | |
| 650 | 4 | |a Schizotypal personality disorder | |
| 650 | 4 | |a Schizotypy | |
| 700 | 1 | |a Cavalletti, Veronica |e verfasserin |4 aut | |
| 700 | 1 | |a Lysaker, Paul H |e verfasserin |4 aut | |
| 700 | 1 | |a Dimaggio, Giancarlo |e verfasserin |4 aut | |
| 700 | 1 | |a Petrocchi, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Chiarello, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Enzo, Consuelo |e verfasserin |4 aut | |
| 700 | 1 | |a Velicogna, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Mancini, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Goldzweig, Gil |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC psychiatry |d 2001 |g 23(2023), 1 vom: 20. Feb., Seite 113 |w (DE-627)NLM113122403 |x 1471-244X |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2023 |g number:1 |g day:20 |g month:02 |g pages:113 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12888-023-04610-5 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2023 |e 1 |b 20 |c 02 |h 113 | ||